AnaptysBio, Inc.
ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE 3 (LAG-3)

Last updated:

Abstract:

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.

Status:
Application
Type:

Utility

Filling date:

1 May 2019

Issue date:

22 Aug 2019